Dymista (azelastine/fluticasone propionate)
Status:
Negotiations were not pursued
Manufacturer:
Meda Pharmaceuticals
Indication:
Seasonal allergic rhinitis
Last updated July 24, 2015
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer
Last updated July 22, 2015
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Thromboembolic events (venous), treatment and prevention of recurrence
Last updated July 9, 2015
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated July 2, 2015
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Last updated June 30, 2015
Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Chronic Hepatitis C
Last updated June 16, 2015
Abilify Maintena (aripiprazole)
Status:
Concluded with an LOI
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Schizophrenia
Last updated June 14, 2015
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Last updated June 2, 2015
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Thrombocytopenia associated with chronic hepatitis c infection
Last updated May 28, 2015
Status:
Negotiations were not pursued
Manufacturer:
Aegerion Pharmaceuticals Canada Ltd.
Indication:
Homozygous Familial Hypercholesterolemia
Last updated May 26, 2015